In patients with luminal B/HER2-positive breast cancer, a combination of trastuzumab, pertuzumab and an aromatase inhibitor (AI) can be used as first-line therapy based upon the PERTAIN study [44]. This evidence concerns the gene CYP19A1 and breast carcinoma.